Pfizer shelves haemophilia gene therapy Beqvez

Pfizer drops Beqvez, leaving gene therapy cupboard bare
Beqvez was Pfizer's first gene therapy, stemming from an alliance with Spark Therapeutics (now part of Roche) more than a decade ago, at a time when it was actively building a presence in gene therapy with an ambition to become "the industry leader" in the category.
Pfizer discontinues hemophilia treatment Beqvez, emptying its gene therapy portfolio
Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia B product Beqvez.
Pfizer stops commercialization of hemophilia gene therapy Beqvez
Pfizer said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing soft demand from patients and their doctors.
Pfizer halts work on hemophilia gene therapy, Nikkei reports
Pfizer (PFE) will end global development and commercialization of Beqvez, a gene therapy for hemophilia, Nikkei learned Thursday, after the
Pfizer Discontinues Hemophilia Gene Therapy Beqvez As Interest Wanes
According to multiple media reports on Thursday, Pfizer Inc. (NYSE:PFE) has terminated the global development and commercialization of its hemophilia B gene therapy, Beqvez. In April 2024, the FDA approved Beqvez for moderate to severe hemophilia B in adult patients who currently use factor IX prophylaxis therapy or have current or historical life-threatening hemorrhage,
National Health Executive7m
Gene therapy breakthrough brings life-changing benefits
In a major breakthrough, four children born with severe visual impairments have experienced life-changing improvements in their ...
pharmaphorum2h
Troubled gene therapy player bluebird sold for a song
12 years after going public, beleaguered gene therapy company bluebird bio will be sold to private equity groups Carlyle and ...
What a $2 million per dose gene therapy reveals about drug pricing
Vincent Gaynor remembers, almost to the minute, when he realized his part in birthing the breakthrough gene therapy Zolgensma ...
Sensorion’s Phase I/II gene therapy trial to continue with DMC recommendation
Sensorion's Audiogene Phase I/II trial of the SENS-501 gene therapy programme has received a favourable recommendation from ...
Rolling Out19h
Advanced gene therapy lights hope for vision loss patients
Revolutionary gene therapy approaches show promise in treating various retinal conditions, potentially transforming treatment ...
Pharmaceutical Technology51m
MeiraGTx seeks UK approval after gene therapy restores sight in children born blind
MeiraGTx’s investigational gene therapy AAV-AIPL1 has improved the sight of 11 children who were born blind. MeiraGTx is ...
Latus Bio Announces Data Presentations in Support of its Preclinical Huntington’s Disease Gene Therapy Program
Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, is pleased to announce data ...
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker
Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.
6-Year-Old Boy Who Was Born Blind Gets Vision Partially Restored After ‘Life-Changing’ Gene Therapy
A Connecticut boy is among four children all born with severe childhood blindness who gained “life-changing improvements” to ...
ophthalmologytimes2d
Envision Summit 2025: Beyond the status quo in gene therapy
At the Envision Summit 2025 in San Juan, Puerto Rico, Mike Farkas, MD, discussed gene therapy research for retinal ...
Gene therapy maker bluebird to go private in discounted deal amid cash crunch
By Sneha S K (Reuters) -Gene therapy maker bluebird bio on Friday agreed to be taken private by Carlyle Group and SK Capital ...